Document:

Exhibit 10.1

 

ARGOS THERAPEUTICS, INC.

4233 TECHNOLOGY DRIVE

DURHAM, NC 27704

 

 

July 1, 2016

 

VIA email

 

Richard D. Katz

209 Sierra Drive

Chapel Hill, NC 27514

 

Dear Rich:

 

I am pleased to extend to you this offer
of employment with Argos Therapeutics, Inc. (“Argos Therapeutics”) by way of this offer letter (the “Offer
Letter”). We at Argos Therapeutics are excited about the challenges and opportunities that lie ahead for us collectively
and are enthusiastic about the prospect of you joining the Argos Therapeutics team. We look forward to your favorable response
to this. If you choose to accept the Company’s offer, your employment at Argos Therapeutics shall commence no later than
Monday, July 11, 2016.

 

The details of this offer are as follows:

 

		1.	Position and Duties.  You shall serve, on a full-time basis, as the Company’s
VP and Chief Financial Officer reporting to the Company’s Chief Executive Officer.  You agree to perform the duties
of your position and such other duties as reasonably may be assigned to you from time to time.  You also agree that while
employed by the Company, you will devote your full business time and your best efforts, business judgment, skill and knowledge
exclusively to the advancement of the business and interests of the Company and to the discharge of your duties and responsibilities
for it, except as approved by the Company.

 

		2.	Compensation and Benefits.  During your employment, as compensation for all services
performed by you for the Company and subject to your performance of your duties and responsibilities for the Company, pursuant
to this Agreement or otherwise, the Company will provide you the following pay and benefits:

 

		(a)	Base Salary. Your base salary in this position will be at the rate of $300,000 per year,
less all applicable taxes and deductions, and shall be paid semi-monthly in accordance with the Company’s standard payroll
schedule. First and last payments will be adjusted to reflect partial periods worked.

 

		(b)	Bonus Compensation. During your employment and subject to the approval of the Company’s
Board of Directors (the “Board”), you will be eligible for an annual performance bonus of up to 40% of your
annualized base salary (the “Target Bonus”), based upon your personal performance and the Company’s performance
during the applicable calendar year, as determined by the Company in its sole discretion. Any bonus due to you hereunder will be
paid not later than the 15th of March following the year to which the bonus relates, subject to your continuous employment
through the date the bonus is paid.  The foregoing shall be construed and applied so that any bonus payable to you is paid
to you so as to qualify as a “short-term deferral” under Section 409A of the Internal Revenue Code of 1986, as
amended (the “Code”) (Section 409A of the Code, together with the regulations thereunder, “Section 409A”).

 

		(c)	Equity. Within ten days of your start date, you will be granted non-statutory stock options
to purchase 300,000 shares of Argos Therapeutics common stock at an exercise price equal to the closing share price on the date
of grant. This award shall be an inducement grant and, as such, is not formally subject to the terms and conditions of Argos’
2014 Stock Incentive Plan. However, consistent with the bulk of awards made under the Plan, the options will vest over four years
from your start date (with 25% vesting after one full year of service and then monthly over the next 36 months) and will be subject
to other terms and conditions substantially similar to those applicable to awards made under Argos’ 2014 Stock Incentive
Plan. This grant of 300,000 shares is equal to approximately 0.94% of Argos’ total shares outstanding as of the date of this
letter agreement.

 

    A-1 

     

    

		(d)	Participation in Employee Benefit Plans.  You will be entitled to participate in all
employee benefit plans from time to time in effect for employees of the Company generally, except to the extent such plans are
duplicative of benefits otherwise provided to you under this Agreement (e.g., severance pay) or under any other agreement. 
Your participation will be subject to eligibility and the terms of the applicable plan documents and applicable Company policies.
Argos Therapeutics provides the following benefits to regular, full-time employees includes the following:
	 	 	 

			

		·	Medical Insurance

		·	Dental Insurance

		·	Vision Insurance

		·	Life and AD&D Insurance

		·	Short Term Disability

		·	Long Term Disability

		·	Long Term Care

		·	Eleven paid holidays per year

		·	401(k) Savings and Investment Plan

		·	Flexible Spending Account

		·	Paid Time Off (PTO) eligibility based on service with the Company and initially prorated at 16.67
hours per month (equivalent to 25 days per year)

Notes:

		o	Argos Therapeutics pays 100% of all individual benefit premiums and 50% of dependent premiums.

		o	If your employment terminates for any reason whatsoever, you may not be entitled to receive any
cash payment for unused paid time off accrued to the date of your termination.

 

Argos Therapeutics will regularly
review all its benefit plans and reserves the right to change or terminate such plans at any time at its sole discretion, with
or without prior notice to you.

 

		(e)	Business Expenses.  The Company will pay or reimburse you for all reasonable business
expenses incurred or paid by you in the performance of your duties and responsibilities for the Company, subject to any maximum
annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation
as the Company may specify from time to time.  Any reimbursement that constitutes nonqualified deferred compensation subject
to Section 409A shall be subject to the following additional rules: (i) no reimbursement of any such expense shall affect
your right to reimbursement of any other such expense in any other taxable year; (ii) reimbursement of the expense shall be
made, if at all, not later than the end of the calendar year following the calendar year in which the expense was incurred; and
(iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit.

 

		3.	Severance. The Company will provide you with the following severance payments as a condition
of your employment:

 

		(a)	Termination Without Cause or for Good Reason. If your employment is terminated by
the Company Without Cause or by you for Good Reason, then (subject to your executing and not revoking the Separation Agreement
and Release of All Claims (the “Release,” attached hereto as Exhibit A), the Company will: (i)
pay you an amount equal to 9 months of your then-current base salary, less standard employment-related withholdings and deductions,
with such payments to be made in 9 equal monthly installments in accordance with the Company’s usual payroll practices beginning
on the first regular pay date following the termination date; and (ii) provide for continued coverage, at the Company’s expense,
under the Company’s medical plan to the extent permitted under such plans for a period of 9 months immediately following
the date of termination of your employment; provided, however, that if health insurance coverage is not available to non-employees
under the Company sponsored plan, the Company shall reimburse you in an amount equal to the cost of the premium for coverage under
a medical plan at the same average level and on the same terms and conditions which applied immediately prior to the date of your
termination.

 

    A-2 

     

    

		(b)	Termination Without Cause or for Good Reason Following a Change in Control. Notwithstanding
the foregoing, if your employment is terminated by the Company or its successor in interest Without Cause or by you for Good Reason
within ninety (90) days before or within six months after a Change in Control Event (as defined in the Company’s 2014 Stock
Incentive Plan) that also qualifies as a “change in control event” within the meaning of Treasury Regulation Section
1.409A-3(i)(5)(i) (a “Company Change in Control”) then (subject to your executing and not revoking the Release)
the Company will (i) pay you an amount equal to 9 months of your then-current base salary, less standard employment-related
withholdings and deductions, with such payments to be made in 9 equal monthly installments in accordance with the Company’s
usual payroll practices beginning on the first regular pay date following the termination date; (ii) pay you an amount equal to
9 months of the Target Bonus, less standard employment-related withholdings and deductions, with such payments to be made in 9
equal monthly installments in accordance with the Company’s usual payroll practices beginning on the first regular pay date
following the termination date; and (iii) provide for continued coverage, at the Company’s expense, under the Company’s
medical plan to the extent permitted under such plans for a period of 9 months immediately following the date of termination of
your employment; provided, however, that if health insurance coverage is not available to non-employees under the Company sponsored
plan, the Company shall reimburse you in an amount equal to the cost of the premium for coverage under a medical plan at the same
average level and on the same terms and conditions which applied immediately prior to the date of your termination.

 

		(c)	Definition of “Cause.” For purposes hereof, “Cause” shall
mean that: (i) you failed to attempt in good faith, refused or willfully neglected to perform and discharge your material
duties and responsibilities; (ii) you have been convicted of, or pled nolo contendere to, a felony or other crime
involving fraud or moral turpitude; (iii) you breached your fiduciary duty or loyalty to the Company, or acted fraudulently
or with material dishonesty in discharging your duties to the Company; (iv) you undertook an intentional act or omission of
misconduct that materially harmed or was reasonably likely to materially harm the business, interests, or reputation of the Company;
(v) you materially breached any material provision hereof; or (vi) you materially breached any material provision of
any Company code of conduct or ethics policy. Notwithstanding the foregoing, “Cause” shall not be deemed to have occurred
unless: (A) the Company provides you with written notice that it intends to terminate your employment hereunder for one of
the grounds set forth in subsections (i), (v) or (vi) within sixty (60) days of such reason(s) occurring, (B) if
such ground is capable of being cured, you have failed to cure such ground within a period of thirty (30) days from the date
of such written notice, and (C) the Company terminates your employment within six (6) months from the date that Cause
first occurs.

 

		(d)	Definition of “Good Reason.” For purposes hereof, “Good Reason”
shall mean, without your written consent: (i) any change in your position, title or reporting relationship with the Company
that diminishes in any material respect your authority, duties or responsibilities; provided, however,
that a change in your authority, duties or responsibilities solely due to the Company becoming a division, subsidiary or other
similar part of a larger organization, shall not by itself constitute Good Reason; (ii) any material reduction in your base
compensation; (iii) a material change in the geographic location at which services are to be performed by you; or (iv) a
material breach of any provision hereof by the Company or any successor or assign. Notwithstanding the foregoing, “Good Reason”
shall not be deemed to have occurred unless: (A) you provide the Company with written notice that you intend to terminate
your employment hereunder for one of the grounds set forth in subsections (i), (ii), (iii) or (iv) within sixty (60) days
of such reason(s) occurring, (B) if such ground is capable of being cured, the Company has failed to cure such ground within
a period of thirty (30) days from the date of such written notice, and (C) you terminate your employment within six (6) months
from the date that Good Reason first occurs. For purposes of clarification, the above-listed conditions shall apply separately
to each occurrence of Good Reason and failure to adhere to such conditions in the event of Good Reason shall not disqualify you
from asserting Good Reason for any subsequent occurrence of Good Reason.

 

		(e)	Release of Claims. The Company shall not be obligated to pay you the severance payments
provided for herein unless you have timely executed (and not revoked) a separation agreement in substantially the form attached
hereto as Exhibit A. Such separation agreement must be executed and become binding and enforceable within sixty (60) calendar
days after the effective date of your termination of employment (such 60th day, the “Payment Commencement Date,”).
Subject to the preceding sentence, payment of any severance payments due hereunder shall commence on the Payment Commencement Date.

 

    A-3 

     

    

		4.	Parachute Payment. 

		(a)	In the event of a consummation of a change in ownership or control (within the meaning of Section
280G of the Code and the regulations thereunder (“Section 280G”) (a “280G Change in Control”)
(as defined herein) payments and benefits under this Agreement, together with other payments and benefits provided to you by the
Company (including, without limitation, any accelerated vesting of stock options, shares of restricted stock or other equity-based
awards) (the “Total Payments”), shall be made with regard to whether the deductibility of the Total Payments
would be limited or precluded by Section 280G and without regard to whether the Total Payments would subject you to the federal
excise tax levied on certain “excess parachute payments” under Section 4999 of the Code (the “Excise Tax”).
If any portion of the Total Payments constitutes an “excess parachute payment” within the meaning of Section 280G (the
aggregate of such payments (or portions thereof) being hereinafter referred to as the “Excess Parachute Payments”),
You will be entitled to receive: (i) an amount limited so that no portion thereof shall fail to be tax deductible under Section
280G of the Code (the “Limited Amount”), or (ii) if the amount otherwise payable hereunder or otherwise (without regarding
to clause (i)) reduced by all taxes applicable thereto (including, for the avoidance of doubt, the Excise Tax) would be greater
than the Limited Amount reduced by all taxes applicable thereto, the amount otherwise payable hereunder.

		(b)	The determination as to whether the Total Payments include Excess Parachute Payments and, if so,
the amount of such Excess Parachute Payments, the amount of any Excise Tax with respect thereto, the amount of any Gross-up Payment,
if applicable, and the amount of any reduction in Total Payments shall be made at the Company’s expense by the independent
public accounting firm most recently serving as the Company’s outside auditors or such other accounting or benefits consulting
group or firm as the Company may designate (the “Accountants”). In the event that any payments under this Agreement
or otherwise are required to be reduced as described in Section 4(b), the adjustment will be made, first, by reducing the amount
of base salary and bonus payable pursuant to Sections 3(a)(i) or the amount of base salary and bonus payable pursuant to
Section 3(b)(i)-(ii), as applicable; second, if additional reductions are necessary, by reducing the payment of or reimbursement
for COBRA premiums due to you pursuant to Section 3(a)(ii) or Section 3(b)(iii), as applicable; and third,
if additional reductions are still necessary, by eliminating the accelerated vesting of time-based equity-based awards or the vesting
of performance-based equity-based awards, if any, starting with those awards for which the amount required to be taken into account
under Section 280G is the greatest.

		(c)	In the event that there has been an underpayment or overpayment under this Agreement or otherwise
as determined by the Accountants, the amount of such underpayment or overpayment shall forthwith be paid to you or refunded to
the Company, as the case may be, with interest at the applicable federal rate provided for in Section 7872(f) (2) of the Code.

 

		5.	Prohibited Competition and Solicitation. You acknowledge the competitive and proprietary
aspects of the business of Company and are aware that the Company furnishes, discloses and makes available to you confidential
and Proprietary Information (as defined in the Confidentiality Agreement referenced in Section 8 below) related to Company’s
business and that Company may provide you with unique and specialized knowledge and training. You also acknowledge that the Confidential
Information and specialized knowledge and training have been developed and will be developed by Company through the expenditure
of substantial time, effort and money and that the Confidential Information could be used by you to compete with Company. A business
will be deemed to be “Competitive” with the Company if it performs research, development or commercialization of individualized
cell-based therapy for the treatment of metastatic renal cell carcinoma, HIV or another indication in which the Company has conducted
a clinical trial within twelve months before the end of your employment with the Company. Because of the competitive and proprietary
aspects of the business of the Company, you agree as follows:

 

	 	(a)	
Covenant Not to Compete or Solicit. During your employment with the Company and for one (1) year after the termination
of your employment with Company for any reason, you will not, directly or indirectly, on your behalf or on behalf of another person,
entity or third party anywhere in the United States, engage in the following conduct without the prior written consent of Company:
(i) as officer, director, principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage,
operate or control, or be employed by, provide services to, or engage in or have a financial interest in any business which is
Competitive with Company (other than as specifically permitted by the Company in writing upon written request); (ii) solicit,
divert or appropriate or attempt to solicit, divert or appropriate, the business or patronage of any customers, business partners,
or patrons of Company, or any prospective customers, business partners, or patrons to whom the Company has made a sales presentation
(or similar offering of services or business) within the one (1) year period preceding the date of your termination of employment
with Company; (iii) solicit, entice or persuade or attempt to solicit, entice or persuade any employees of or consultants to Company
or any present or future parent, subsidiary or affiliate of Company to terminate their employment or other engagement with Company
or any such parent, subsidiary or affiliate for any reason; or (iv) interfere with, or attempt to interfere with, the relations
between Company and any customer, vendor or supplier to Company.

 

    A-4 

     

    

	 	(b) 	Reasonableness
of Restrictions. You acknowledges that: (i) the types of employment which are prohibited by this Section 5 are narrow and
reasonable in relation to the skills which represent your principal salable asset both to Company and other prospective employers;
and (ii) the temporal and geographical scope of Section 5 is reasonable, legitimate and fair to you in light of Company’s
need to market its services and sell its products in order to have a sufficient customer base to make Company’s business
profitable and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment
for which you are qualified to earn your livelihood.

 

		6.	Section 409A.

 

		(a)	You and the Company agree that this Agreement shall be interpreted to comply with or be exempt
from Section 409A, and the regulations and guidance promulgated thereunder to the extent applicable, and all provisions of
this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.

 

		(b)	A termination of employment shall not be deemed to have occurred for purposes of any provision
of this Agreement providing for the payment of any amounts or benefits considered “nonqualified deferred compensation”
under Section 409A upon or following a termination of employment unless such termination is also a “separation from
service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to
a “termination,” “termination of employment” or like terms shall mean “separation from service.” 
If you are deemed on the date of termination to be a “specified employee” within the meaning of that term under Section 409A(a)(2)(B),
then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Section 409A
payable on account of a “separation from service,” such payment or benefit shall be made or provided at the date which
is the earlier of (a) the expiration of the six-month period measured from the date of such “separation from service,”
and (b) the date of your death (the “Delay Period”).  Upon the expiration of the Delay Period, all payments
and benefits delayed pursuant to this Section 11(b) (whether they would have otherwise been payable in a single sum or
in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of
the Delay Period to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided
in accordance with the normal payment dates specified for them herein.

 

		(c)	For purposes of Section 409A, your right to receive any installment payments pursuant to this
Agreement shall be treated as a right to receive a series of separate and distinct payments.

 

		(d)	In no event shall the Company or any of its affiliates have any liability relating to the failure
or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A

 

		7.	At Will Employment. This Offer Letter is not intended to, nor does it, create any employment
contract for any specified term or duration between you and the Company. In accordance with the laws of the State of North Carolina,
your employment with the Company is considered “at will”. This means that, just as you may resign your employment at
any time, Argos Therapeutics may, in its sole discretion, with or without cause, terminate your employment at any time for any
reason.

 

    A-5 

     

    

		8.	Contingencies. This offer of employment includes a 90 day introductory period which is outlined
in the Company’s Employee Handbook, and is also contingent upon the following: satisfactory completion of the Argos Therapeutics
employment application; your ability to begin work on the date indicated below; proof of your authorization to work in the United
States (I-9 Employment Eligibility Verification); execution of a Confidentiality, Inventions and Non-Solicitation Agreement (the
“Confidentiality Agreement”); execution of the Argos Therapeutics Company’s Code of Ethics; execution
of the Argos Therapeutics Certification Regarding Insider Trading and Public Disclosure Policies; and passing a pre-employment
drug screening and background screening to Management’s satisfaction. It is understood and agreed that breach by you of the
Confidentiality Agreement shall constitute a material breach of this Agreement

 

		9.	No Conflicting Agreements. You represent and warrant that you are not bound by any employment
contract, restrictive covenant or other restriction preventing you from continuing employment with or carrying out your responsibilities
for the Company. You agree that you will not disclose or use on behalf of the Company any proprietary information of any third
party without that party’s consent.

 

		10.	General.

 

		(a)	Notices.  Any notices provided for in this Agreement shall be in writing and shall
be effective when delivered in person, consigned to a reputable national courier service for overnight delivery or deposited in
the United States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the
case of the Company, to it by notice to the Chairman of the Board of Directors, c/o Argos Therapeutics, Inc., at its principal
place of business, or to such other address(es) as either party may specify by notice to the other actually received.

 

		(b)	Entire Agreement. This Offer Letter, together with the Confidentiality Agreement and other
agreements specifically referred to herein, sets forth the entire agreement between you and the Company and replaces all prior
communications, agreements and understandings, whether oral or written, with respect to your and understandings relating to your
employment with the Company. The terms and conditions of this Agreement may only be modified or amended by a written agreement
executed by and the Company.

		(c)	Successors and Assigns. The Company may assign its rights and obligations hereunder to any
person or entity that succeeds to all or substantially all of Company’s business or that aspect of Company’s business
in which you are principally involved. You may not assign your rights and obligations under this Agreement without the prior written
consent of Company.

 

		(d)	Severability.  If any portion or provision of this letter Agreement is deemed to any
extent illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement will not be affected
and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law

 

		(e)	Governing Law and Venue. This letter shall be governed
by and construed in accordance with the laws of the State of North Carolina (without reference to the conflicts of law provisions
thereof). Any action, suit, or other legal proceeding which is commenced to resolve any matter arising under or relating to any
provision of this letter shall be commenced only in a court in Durham County, North Carolina (or, if appropriate, a federal court
located within North Carolina). 

		(f)	Counterparts. This Agreement may be executed in two or more counterparts, each of which
will be deemed an original and all of which together shall constitute one and the same instrument. A signature by fax shall be
treated as an original.

 

By your signature below, you represent
and warrant to the Company that you: (i) are not subject to any employment, noncompetition or other similar agreement that would
prevent or interfere with the Company’s employment of you on the terms set forth herein; and (ii) have not brought and will
not bring with you to the Company, any materials or documents of a former employer which are not generally available to the public
or which did not belong to you prior to your employment with the Company, unless you have obtained written authorization from the
former employer or other owner for their possession and use and provided the Company with a copy thereof.

 

    A-6 

     

    

If our employment offer is satisfactory,
please sign and date a copy of this letter in the space provided below as well as the accompanying documents, including the Confidentiality
Agreement, Code of Ethics, and Certification Regarding Insider Trading and Public Disclosure Policies and return them Joan Winterbottom,
VP and Chief Human Resources Officer, no later than Tuesday, July 5, 2016. If the offer is not accepted by this date, it shall
expire. At the time you sign and return it, this Offer Letter will take effect as a binding agreement between you and the Company
on the basis set forth above.  We are looking forward to working with you in contributing to the growth of Argos Therapeutics.

 

 

Sincerely,

 

 

/s/ Joan C. Winterbottom

VP and Chief Human Resources Officer

 

Enclosures (as stated)

 

I accept the Company’s employment
offer for the position of VP and Chief Financial Officer subject to the terms and conditions outlined above.

 

 

	Signed:	 	 /s/ Richard D. Katz	 	 	 	 	 
	 	 	 	 	 	 	 	 
	Date Signed: 	 	 July 6, 2016 	 	Start Date:	 	July 11, 2016	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 

 

 

 

    A-7 

     

    

EXHIBIT A

 

SEPARATION AGREEMENT AND RELEASE OF CLAIMS

 

Argos Therapeutics,
Inc., a Delaware corporation (the “Company”), and Richard D. Katz (the “Employee”) (together,
the “Parties”) accepted an offer of employment with the Company pursuant to the terms of the offer letter dated
July 1, 2016 (the “Offer Letter”). Any capitalized terms not defined herein shall have the meanings ascribed
to them in the Offer Letter. This is the release by Employee of all claims against the Releasees (as defined below) arising out
of the Employee’s employment with or separation from the Company (the “Release”). The consideration for
the Employee’s agreement to this Release consists of the severance payments and benefits set forth in Section 3 of the
Offer Letter, which are conditioned on, among other things, termination of the Employee’s employment by the Company without
Cause or by the Employee for Good Reason and effectiveness of this Release based on the Employee’s timely execution and non-revocation
hereof.

 

1. Tender of Release.
This Release is automatically tendered to the Employee upon the termination of the Employee’s employment by the Company without
Cause or by the Employee with Good Reason.

 

2. Release of
Claims. The Employee voluntarily, fully, forever, irrevocably and unconditionally releases and discharges the Company, its
affiliates, subsidiaries and parent companies and each of their predecessors, successors, assigns, and their current and former
members, partners, directors, managers, officers, employees, representatives, attorneys, agents, and all persons acting by, through,
under or in concert with any of the foregoing (any and all of whom or which are hereinafter referred to as the “Releasees”),
from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions,
causes of action, suits, rights, demands, costs, losses, debts and expenses (including attorney’s fees and costs actually
incurred), of any nature whatsoever, known or unknown that the Employee now has, owns or holds, or claims to have, own, or hold,
or that he at any time had, owned, or held, or claimed to have had, owned, or held against any Releasee arising out of the Employee’s
employment with or separation from the Company (collectively, “Claims”). This release of Claims includes, without
implication of limitation, the release of all Claims:

 

	 	•	 	of breach of contract; 

 

	 	•	 	of retaliation or discrimination under federal, state or local law (including, without limitation, Claims of age discrimination or retaliation under the Age Discrimination in Employment Act, Claims of disability discrimination or retaliation under the Americans with Disabilities Act, Claims of discrimination or retaliation under Title VII of the Civil Rights Act of 1964 and Claims of discrimination or retaliation under state law); 

 

	 	•	 	under any other federal or state statute, to the fullest extent that Claims may be released; 

 

	 	•	 	of defamation or other torts; 

 

	 	•	 	of violation of public policy; 

 

	 	•	 	for wages, salary, bonuses, vacation pay or any other compensation or benefits; and 

 

	 	•	 	for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees. 

Notwithstanding anything to the contrary
contained herein, this Release does not apply to or affect (i) the Employee’s right to receive the severance payments
set forth in Section 3 of Offer Letter , (ii) the Employee’s right to be reimbursed for reasonable business expenses
incurred prior to termination of the Employee’s employment according to the terms of Section 2(e) of the Offer Letter; (iii)
the Employee’s ownership of, and the Employee’s rights by virtue of his ownership of, any capital stock or other securities
of the Company, (iv) any rights of indemnification or exculpation of which the Employee is the beneficiary under any separate
contractual indemnification agreement with the Company in connection with his service as a director or officer of the Company,
the corporate charter, bylaws or other charter or organizational instruments or benefit or equity plans of the Company or any other
Releasee or at law and rights of coverage to which the Employee may be entitled under any director and officer liability insurance
policy of the Company or any other Releasee or (v) for purposes of clarity, any Claim arising out of any matters or events
occurring after the effective date of the Release.

 

    A-8 

     

    

4. Ongoing Obligations
of the Employee; Enforcement Rights. The Employee reaffirms his ongoing obligations as well as the Company’s enforcement
rights provided for in Sections 6, 7 and 8 of the Offer Letter.

 

5. No Assignment;
Representation on Action. The Employee represents that he has not assigned to any other person or entity any Claims against
any Releasee. The Employee further represents that he has not filed or reported any Claims against any Releasee with any state,
federal or local agency or court.

 

6. Right to Consider
and Revoke Release. The Employee acknowledges that he has been given the opportunity to consider this Release for a period
ending forty-five (45) days after the tender of the Release. In the event the Employee executed this Release within less than forty-five
(45) days after the tender of the Release, he acknowledges that such decision was entirely voluntary and that he had the opportunity
to consider this Release until the end of the forty-five (45) day period. To accept this Release, the Employee shall deliver
a signed Release to the Chairman of the Compensation Committee of the Board (the “Chair”) within such forty-five
(45) period. For a period of seven (7) days from the date when the Employee executes this Release (the “Revocation Period”),
he shall retain the right to revoke this Release by written notice that is received by the Chair on or before the last day of the
Revocation Period. This Release shall take effect only if it is executed within the forty-five (45) day period as set forth
above and if it is not revoked pursuant to the preceding sentence. If those conditions are satisfied, this Release shall become
effective and enforceable on the date immediately following the last day of the Revocation Period.

 

7. Other Terms.

 

(a) Legal Representation;
Review of Release. The Employee acknowledges that he has been advised to discuss all aspects of this Release with his attorney,
that he has carefully read and fully understands all of the provisions of this Release and that he is voluntarily entering into
this Release.

 

(b) Binding Nature
of Release. This Release shall be binding upon the Employee and upon his heirs, administrators, representatives and executors.

 

(c) Modification
of Release; Waiver. This Release may be amended, only upon a written agreement executed by the Employee and the Company.

 

(d) Severability.
In the event that at any future time it is determined by an arbitrator or court of competent jurisdiction that any covenant, clause,
provision or term of this Release is illegal, invalid or unenforceable, the remaining provisions and terms of this Release shall
not be affected thereby and the illegal, invalid or unenforceable term or provision shall be severed from the remainder of this
Release. In the event of such severance, the remaining covenants shall be binding and enforceable.

 

(e) Governing
Law and Venue. This Release shall be deemed to be made and entered into in the State of North Carolina and shall in all respects
be interpreted, enforced and governed under the laws of the State of North Carolina without giving effect to the conflict of law
provisions of North Carolina law that would require the application of law of any other jurisdiction. The language of all parts
of this Release shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against either
of the Parties. Any action, suit or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision hereunder shall be commenced only in a court in Durham County, North Carolina
(or, if appropriate, a federal court located within North Carolina). 

 

(f) Absence of
Reliance. The Employee acknowledges that he is not relying on any promises or representations by the Company or its agents,
representatives or attorneys of either of them regarding any subject matter addressed in this Release.

 

    A-9 

     

    

So agreed by the Employee:

	 	 	 
	
         
	 	
         

	/s/ Richard D. Katz	 	Date

 

 

 

 

 

 

 

 

 

A-10EX-10.1

 Exhibit 10.1 

DISTRIBUTION AND LICENSE AGREEMENT 

THIS DISTRIBUTION AND LICENSE AGREEMENT (“Agreement”) dated as of June 7, 2016 (“Effective Date”), is
entered into between Angionetics Inc., a Delaware corporation having its principal place of business at 11750 Sorrento Valley Rd., Suite 250, San Diego, CA 92121 (“Angionetics”), a wholly-owned subsidiary of Taxus Cardium
Pharmaceuticals, Inc. (“Taxus Cardium”) and Pineworld Capital Limited, a corporation having its principal place of business at Flat 01A, 10/F Carnival Commercial Building 18 Java Road, North Point, Hong Kong (“Licensee”).

 BACKGROUND 
 A.
Angionetics is developing an angiogenic gene therapy treatment, known as Generx (as further defined below, the “Product”). Angionetics owns or controls certain patents, know-how and other intellectual property relating to such
Product; 
 B. Licensee desires to develop and commercialize Products in the China, and Angionetics desires to have the Product developed
and commercialized in China by Licensee, all in accordance with this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants herein contained, and intending to be legally bound, the Parties hereby agree as follows: 
 ARTICLE 1

 DEFINITIONS 
 1.1
“Affiliate” of a Party shall mean any person, corporation or other entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party, as the case may be,
for as long as such control exists. With respect to Licensee, Affiliate includes a company or other entity that is controlled by, or under common control with Huapont Life Sciences Co. Ltd. or its shareholders, Zhang Songshan or Zhang Yizhuo. As
used in this Section 1.1, “control” shall mean: (a) to possess, directly or indirectly, the power to direct the management and policies of such person, corporation or other entity, whether through ownership of voting
securities or by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction) of the voting share capital in such person, corporation or other entity. 
 1.2
“Angionetics IP” shall mean the Angionetics Know-How and Angionetics Patents. 
 1.3 “Angionetics
Know-How” shall mean all scientific, medical, technical, regulatory, manufacturing and other information relating to the Product (including Data): (a) to the extent Controlled by Angionetics or its Affiliates as of the Effective Date
or during the term of this 

  
 - 1 - 

 
Agreement, and (b) that are necessary for Licensee to exercise its rights or perform its obligations under this Agreement. 

1.4 “Angionetics Patents” shall mean all issued, unexpired patents and all reissues, renewals, re-examinations and extensions
thereof, and patent applications therefor, and any divisions or continuations, in whole or in part, thereof, including those patents and applications set forth in Exhibit 1.4: (a) to the extent Controlled by Angionetics or its Affiliates
as of the Effective Date or during the term of this Agreement and (b) that would, but for the license granted hereunder, be infringed by use, development, manufacture, formulation, packaging, import, sale, distribution, promotion or marketing
of the Product, for the purposes of use and/or sale in the Territory. 
 1.5 “Annual Net Sales” shall mean total Net Sales
in the Territory in a particular calendar year. 
 1.6 “Applicable Laws” means the applicable provisions of any and all
national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits (including Marketing Approvals) of or from any
court, arbitrator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item. 
 1.7
“BLA” shall mean a biologic license application (or its equivalent) submitted to the CFDA. 
 1.8 “CFDA”
shall mean the China Food and Drug Administration, or any successor entity thereto performing similar functions. 
 1.9
“Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a Party with respect to any objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to
accomplish a similar objective under similar circumstances; Licensee will be deemed to have exercised Commercially Reasonable Efforts if Licensee has exercised those efforts normally used by a pharmaceutical or biotechnology company of similar size
and similar resources, with respect to a compound, product or product candidate, as applicable of similar modality, which compound, product or product candidate is of similar market potential in such country, and is at a similar stage in its
development or product life cycle, taking into account all relevant factors in effect at the time such efforts are to be expended. It is expressly understood that the use of Commercially Reasonable Efforts may result in ceasing the development,
Regulatory Approval or Commercialization of Compounds and/or Products. Further, to the extent that the performance of a Party’s obligations hereunder is adversely affected by the other Party’s failure to perform its obligations hereunder,
the impact of such performance failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations. 

1.10 “Compound” means Ad5FGF-4, alferminogene tadenovec, an angiogenic gene therapeutic. 

  
 - 2 - 

 1.11 “Control” (including any variations such as “Controlled”
and “Controlling”) shall mean, in the context of intellectual property rights, Data or information, possession of the ability to grant an assignment, license or sublicense to such intellectual property, Data and/or information,
and/or to disclose and deliver such Data and/or information, as the case may be, of or within the scope set forth in this Agreement, without violating the terms of any agreement or other arrangement with any Third Party. 

1.12 “Data” shall mean any and all research data, pharmacology data, preclinical data, clinical data and/or all regulatory
documentation, information and submissions pertaining to, or made in association with an IND, Marketing Approval Application, Marketing Approval or the like for, the Compound or a Product, in each case that are Controlled by a Party as of the
Effective Date or during the term of this Agreement. Data also shall include any such data generated by or under authority of Licensee or its Affiliates during the term of this Agreement. 

1.13 “Field” shall mean a treatment for patients with refractory angina, with myocardial ischemia, and other adverse medical
conditions resulting from cardiac microvascular insufficiency. 
 1.14 “First Commercial Sale” shall mean the first bona
fide, arm’s length sale of a Product in the Territory following receipt of Marketing Approval of such Product in the Territory. 

1.15 “IND” shall mean any Chinese filing with the CFDA that is comparable to an Investigational New Drug Application
(including any amendments thereto) filed with the FDA pursuant to 21 C.F.R. §321 before the commencement of clinical trials of a Product. 

1.16 “Marketing Approval” shall mean all approvals, licenses, registrations or authorizations of the Regulatory Authority in
a country, necessary for the manufacture, use, storage, import, marketing and sale of a Product in such country, excluding any governmental pricing and/or reimbursement approvals and/or authorizations. 

1.17 “Net Proceeds” shall mean payments received by Licensee from a Third Party in exchange for the sublicense of rights
under this Agreement, in the form of cash or securities, in consideration for and to the extent reasonably allocable to grant of such Sublicense, after deducting all documented Compound and Product clinical and commercial development costs paid by
Licensee during such period. For clarity, Net Proceeds will not include: (a) amounts to fund costs incurred after the date of the Sublicense at commercially reasonable rates, in connection with the research and development of the Compound
and/or Product; (b) bona fide loans; (c) amounts paid for supplies of Compound or Product or other tangible materials; (d) amounts paid for securities sold to a Sublicensee at fair market value; (e) running royalties (including
any amounts paid based upon sales or profits from the sales of Product); and (f) amounts received in connection with a merger, consolidation or sale of substantially all of the business or assets of Licensee. 

1.18 “Net Sales” shall mean the gross amount billed or invoiced by Licensee, its Affiliates and/or Sublicensees for all sales
of Product to Third Party customers in bona fide arm’s length transactions, less reasonable and customary deductions allowed to the Third Party customer by the selling party, to the extent actually taken by such Third Party, on such sales for:
(a) quantity, trade, cash or other discounts, allowances, credits or rebates (including customer 

  
 - 3 - 

 
rebates); (b) amounts deducted, repaid or credited by reason of rejections or returns of goods and government mandated rebates, or because of chargebacks or retroactive price reductions;
(c) charges for freight, handling, postage, transportation, insurance and other shipping charges to the extent related to the transfer of Product and separately identified on the invoice or other documentation maintained in the ordinary course
of business; and (d) taxes, tariffs, duties or other governmental charges or assessments (including any sales, value added or similar taxes other than an income tax) imposed on the importation or sale of Product to Third Parties and separately
identified on the invoice or other documentation maintained in the ordinary course of business. To the extent applicable, components of Net Sales shall be determined in the ordinary course of business in accordance with historical practice and using
the accrual method of accounting in accordance with generally accepted accounting principles in the Territory. For the purposes of calculating Net Sales, the Parties understand and agree that (i) sales between Licensee and its Affiliates for
resale shall be excluded from the computation of Net Sales and no payments will be payable on such sales except where such Affiliates are end users; and (ii) Net Sales shall not include Products distributed for product development purposes,
including for use in clinical trials, or for compassionate use programs. If a Product is sold or transferred for consideration other than cash, the Net Sales from such sale or transfer shall be deemed the then fair market value of such Product. 

1.19 “Party” shall mean Angionetics or Licensee individually, and “Parties” shall mean Angionetics and
Licensee collectively. 
 1.20 “Patent(s)” shall mean any patents and patent applications (whether provisional or
nonprovisional), together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates and renewals of any of
the foregoing. 
 1.21 “Product” shall mean any biopharmaceutical product containing the Compound, alone or in combination
with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof. 

1.22 “Regulatory Authority” shall mean the CFDA, or a regulatory body with similar regulatory authority in any other
jurisdiction. 
 1.23 “Sublicensee” means a Third Party, other than a distributor, that has been granted by Licensee a
right to sell, market, distribute and/or promote a Product under the grants in Section 2.1; and “Sublicense” shall mean an agreement or arrangement granting such rights. As used in this Agreement, “Sublicensee” shall
not include a wholesaler or reseller of the Product who does not market or promote the Product. 
 1.24 “Territory” shall
mean mainland China. 
 1.25 “Third Party” shall mean any person, corporation, joint venture or other entity, other than
Angionetics, Licensee and their respective Affiliates. 

  
 - 4 - 

 ARTICLE 2 

GRANT OF LICENSE 
 2.1
License. Subject to the terms and conditions of this Agreement, Angionetics hereby grants to Licensee and its Affiliates a royalty-bearing, sublicensable exclusive license during the term of this Agreement under the Angionetics IP to: 

(a) develop the Compounds or Products, including the development of derivative products; 

(b) use, demonstrate or test the Compounds or Products in the Territory, including use in clinical trials and related procedures necessary to
secure Marketing Approval in the Territory; 
 (c) manufacture, make, and have made, the Compounds and/or Products, subject to the terms and
conditions set forth in Article 7, solely for use in the Territory and in the Field; 
 (d) import the Compounds and/or Products into the
Territory; 
 (e) offer for sale, sell, market, distribute and promote Compounds and/or Products, solely in the Territory for use in the
Field. 
 The rights and licenses in this Section 2.1 shall be exclusive even as to Angionetics. 

2.2 Affiliates; Sublicensees. Licensee shall have the right, in accordance with this Section 2.2, to extend the licenses granted
under Section 2.1 above to its Affiliates, solely for so long as such entity remains an Affiliate of Licensee. Licensee shall also have the right to grant sublicenses under the license granted to Licensee under Section 2.1. Licensee shall
ensure that each of its Affiliates and sublicensees is bound by a written agreement containing provisions at least as protective of the Compound, Products and Angionetics as contained in this Agreement. In any event, Licensee shall remain
responsible to Angionetics for all activities of its Affiliates and sublicensees to the same extent as if such activities had been undertaken by Licensee itself and Licensee shall be responsible for the payment to Angionetics of all royalties
payable with respect to the activities and Net Sales of any Affiliate or Sublicensee. 
 2.3 Activities Outside the Territory.
Neither Licensee nor its Affiliates will develop, file for Marketing Approval with respect to, use, make, have made, market, import, export, distribute, promote or sell the Compound and/or Product (nor assist or facilitate any Third Party in doing
any of the foregoing) anywhere in the world, except in the Territory. 
 2.4 No Other Rights. Except for the rights and licenses
expressly granted in this Agreement, Angionetics retains all rights under its intellectual property including the Angionetics IP, and no additional rights shall be deemed granted to Licensee by implication, estoppel or otherwise. For clarity, the
licenses and rights granted in this Agreement shall not be construed to convey any licenses or rights under the Angionetics Patents with respect to any active pharmaceutical ingredient other than the Compound. 

  
 - 5 - 

 2.5 Exclusivity. The license rights granted under Section 2.1 are exclusive to
Licensee. During the term of this Agreement, Angionetics agrees that neither it, nor any of its Affiliates, nor any third parties appointed by Angionetics or its Affiliates, will develop, promote, distribute, sell or provide the Compound, the
Product or any competing products in the same Field for use in the Territory. 
 ARTICLE 3 

GOVERNANCE 
 3.1 Joint
Steering Committee. Within 30 days after the Effective Date, the Parties shall establish a committee (the “Joint Steering Committee” or “JSC”) to oversee the development, Marketing Approval, manufacturing,
and commercialization of the Product in the Territory. 
 (a) Composition. The JSC will consist of two (2) representatives from
each Party, and at least one representative from each Party shall be a vice president or director level employee of such Party. In case a representative of a Party is unavailable for a scheduled JSC meeting, upon reasonable notice to the other
Party, such Party may substitute in place of such representative for such meeting, a competent person who is authorized by such Party to act on matters that will be presented to the JSC at such meeting. Either Party may also replace its respective
JSC representatives at any time with prior notice to the other Party; provided that the criteria for composition of the JSC set forth in the first sentence of this Section 3.1(a) continues to be satisfied following any such replacement. 

(b) Meetings. The JSC shall meet at least once each calendar quarter during the term of this Agreement, unless otherwise agreed by the
Parties or such other frequency as Parties reasonably mutually agree. Such meeting(s) shall be conducted via teleconference, video conference, in person, or by other mutually agreeable means. At the discretion of each Party, other representatives of
Angionetics or Licensee may attend JSC meetings as non-voting observers. Each Party shall bear its own personnel and travel costs and expenses relating to such Party’s participate in JSC meetings. 

(c) Responsibility. The JSC will: (a) serve as a forum for keeping each Party informed as to material matters in connection with
the development, manufacturing and commercialization of Product for use and/or sale in the Territory; (b) serve as a forum for keeping each Party informed as to material matters in connection with the regulatory filings for Product in the
Territory; (c) facilitate the exchange of Data and other information and/or materials between the Parties; (d) review and approve manufacturing plans for the Compound and Product for use and/or sale in the Territory; and (e) undertake
and/or approve such other matters as are provided for the JSC under this Agreement, or otherwise agreed by the Parties. 
 (d)
Decisions. The objective of the JSC shall be to seek to reach unanimous agreement on all matters. Each Party shall have one (1) vote on the JSC. If the JSC cannot reach agreement on any determination or decision within the scope of the
JSC’s authority within thirty (30) days after the date such matter was initially referred to the JSC, the dispute shall be referred to the CEO of Angionetics and the CEO of Licensee (the “Senior Executives”) who shall meet
promptly and negotiate in good faith to resolve the dispute. If, 

  
 - 6 - 

 
despite such good faith efforts, the Parties are unable to resolve such dispute, Licensee shall have the right to cast a deciding vote. 

(e) Scope of Governance. Notwithstanding the creation of the JSC, each Party shall retain the rights, powers and discretion granted to
it hereunder, and the JSC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein or the Parties expressly so agree in writing. The JSC shall not have the power to amend
or modify this Agreement, and its decisions shall not be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JSC are only those specific issues that are expressly
provided in this Agreement to be decided by the JSC. 
 3.2 Withdrawal. Notwithstanding Section 3.1 above, it is understood that
Angionetics’ participation in the JSC is not an obligation of, or a deliverable to be provided by, Angionetics under this Agreement and that such participation is a right of Angionetics that Angionetics may exercise or waive, in its discretion.
At any time and for any reason, Angionetics shall have the right to withdraw from participation in the JSC upon notice to Licensee referencing this Section 3.2, which notice shall be effective immediately upon receipt (“Withdrawal
Notice”). Following the issuance of a Withdrawal Notice, any plans (including Development Plans and Commercialization Plans), information, materials, Know-How and/or other item that either Party is obligated to provide to the JSC shall be
provided directly to the other Party and any decisions to be made by the JSC shall be made by the mutual agreement of both Parties, except that, if the Parties are unable to mutually agree following escalation of a matter to Senior Executives in
accordance with Section 3.1(d) above, then Licensee shall have the right to decide any matter within the scope of Section 3.1(d). 

ARTICLE 4 
 DEVELOPMENT;
REGULATORY; COMMERCIALIZATION 
 4.1 Development. 

(a) In the Territory. As between the Parties, Licensee shall be responsible for and shall use Commercially Reasonable Efforts to
conduct such clinical trials and to obtain such regulatory approvals, including Marketing Approvals and pricing and/or reimbursement approvals, as may be necessary to commercialize Product for at least one indication in the Territory and in the
Field. Licensee agrees to keep Angionetics reasonably informed as to the progress of its clinical development, manufacturing and regulatory activities relating to Product in the Territory, including its correspondence and meetings with Regulatory
Authorities. It is understood and agreed that all development and manufacturing efforts for the Compound and Product for use in the Territory shall be at the sole cost and expense of Licensee at Licensee’s sole discretion. 

(b) Outside the Territory. Angionetics or its licensee(s) shall be responsible for all development, manufacturing and regulatory
activities with respect to the Compound and Product outside the Territory. 
 (c) AFFIRM Study Angionetics will undertake a planned
AFFIRM 

  
 - 7 - 

 
Study (a summary of which is attached here as Exhibit 4.1), with any such modifications as deemed necessary by the Licensee and cleared by the applicable Regulatory Authorities. Angionetics
agrees to provide Licensee with regular updates regarding the AFFIRM Study (not less than once per calendar quarter), and to provide Licensee with any information reasonably requested by Licensee regarding the AFFIRM Study. 

(d) Reports. Licensee shall provide to Angionetics through the JSC an annual written report within thirty (30) days after each
anniversary of the Effective Date, until First Commercial Sale of the Product, summarizing the development activities undertaken by Licensee and its Affiliates and Sublicensees in the preceding twelve-month period. The report may take the form of a
PowerPoint (or similar) presentation. 
 4.2 Exchange of Data and Know-How. 

(a) By Angionetics. After the Effective Date, upon request by Licensee, Angionetics shall provide Licensee with the Angionetics
Know-How that is necessary for Licensee to develop and/or commercialize Product in the Territory for use in the Field, including, any and all Data from any and all worldwide clinical trials and preclinical studies of the Compound and/or Product
conducted by Angionetics that are completed as of the Effective Date. Angionetics will support Licensee in preparing a BLA for the Territory. 

(b) By Each Party. During the Term, each Party shall provide to the other Party, in a timely fashion and as promptly as possible, all
Data Controlled by such Party, and any and all additional Angionetics Know-How that such Party reasonably considers as necessary for the other Party to develop and/or commercialize Product in the Territory (in the case of Licensee) or outside the
Territory (in the case of Angionetics), for use by such other Party in accordance with this Section 4.2. 
 (c) Use; Disclosure.
Licensee may use and disclose Angionetics Know-How to its Affiliates or Third Parties as required to obtain Marketing Approval for Products in the Territory and/or as necessary in performing its obligations and exercising its rights under and in
accordance with this Agreement, in each case under confidentiality restrictions at least as protective of such information as the provisions of this Agreement, including for cross referencing drug master files or other regulatory filings by
Licensee, its Affiliates and/or sublicensees. Angionetics may only use, and disclose to Affiliates and/or Third Parties, Licensee Data provided by Licensee as is reasonably necessary for developing, manufacturing and/or commercializing Product for
use outside of the Territory; provided that such disclosure shall be made under confidentiality restrictions at least as protective of such information as the provisions of this Agreement. 

4.3 Regulatory Matters. Licensee shall be responsible, at its expense, for filing, obtaining and maintaining approvals for the
development and commercialization of the Compound and each Product in the Territory, including any such IND, BLA or Marketing Approval, as well as pricing or reimbursement approvals in the Territory. Licensee shall be responsible for liaising with
and managing all interactions with Regulatory Authorities in the Territory. To the extent relating to the Compound and/or a Product within the Territory, Licensee shall: 

  
 - 8 - 

 (a) through the JSC, keep Angionetics informed as to all material interactions with the CFDA and
other Regulatory Authorities; and 
 (b) provide Angionetics with a copy of any material documents, information and correspondence submitted
to the CFDA or any other Regulatory Authority within the Territory as soon as reasonably practicable, together with summaries thereof, to the extent such summaries exist. 

4.4 Sharing of Regulatory Filings. Without limiting Section 4.2 above, each Party shall permit the other to access, and shall
provide the other Party with sufficient rights to reference and use in association with exercising its rights and performing its obligations under this Agreement (including the right of Angionetics to commercialize the Product outside of the
Territory), all of such Party’s, its Affiliates’ and, if applicable, its licensees’ Data, regulatory filings and regulatory communications associated with any submissions of BLAs or other regulatory approvals for the Product in such
Party’s respective territory (i.e., in the Territory in the case or Licensee and in the outside of the Territory in the case of Angionetics). If any information or data owned or controlled by Angionetics or its Affiliates is required to be
disclosed by a Regulatory Authority in the Territory, then Angionetics agrees to provide to such data or information to Licensee or the Regulatory Authority. 

4.5 Commercialization in the Territory. Licensee or its Sublicensee(s) shall have the sole right to commercialize the Products in the
Territory and shall use Commercially Reasonable Efforts to commercialize the Product in the Territory for use in the Field. 
 4.6
Reporting; Adverse Drug Reactions. Within one hundred eighty (180) days following the Regulatory Approval of the Product in the Territory, Angionetics will provide a draft Safety Data Exchange Agreement (SDEA) which shall be negotiated
by the Parties in good faith and the Parties will enter into such Safety Data Exchange Agreement that more specifically sets forth the obligations of each Party with respect to the exchange of safety information and will require the Parties to
comply with a standard operating procedure set forth therein governing the collection, investigation, reporting and exchange of safety information with respect to the Compound and Products, including but not limited to adverse events, product
quality, and product complaints, sufficient to permit each Party (and in the case of Angionetics, any of its licensees of the Compound and Products outside the Territory) to comply with their respective legal obligations, all in accordance with
Applicable Law. The SDEA will be promptly updated if required by changes in Applicable Law. Each Party shall keep the other Party informed about any adverse events of which such Party becomes aware or is informed regarding the use of Product in or
outside the Territory. As between the Parties, Licensee shall be responsible for reporting all adverse events/experiences to the appropriate Regulatory Authorities in the Territory, and Angionetics shall be responsible for reporting all adverse
events/experiences to the appropriate Regulatory Authorities in countries outside the Territory, in accordance with the appropriate laws and regulations of the relevant countries and authorities. Licensee shall ensure that its Affiliates comply with
such safety reporting obligations in the Territory. 
 ARTICLE 5 

PAYMENTS 

  
 - 9 - 

 5.1 Royalty Payments. 

(a) Royalty Rate. Subject to the terms and conditions of this Agreement, in further consideration of the rights granted to
Licensee under this Agreement, Licensee shall pay to Angionetics royalties at the rate set out below on the Net Sales of Products in the Territory: 
  

					
	 Annual Net Sales of Product(s) in the Territory
	  	Royalty Rate	 
	 Portion of Annual Net Sales of Products up to and including Fifty Million Dollars
($50,000,000)
	  	 	5.0	% 
	 Portion of Annual Net Sales of Products greater than Fifty Million Dollars ($50,000,000) up to and
including Two Hundred Million Dollars ($200,000,000)
	  	 	6.0	% 
	 Portion of Annual Net Sales of Products greater than Two Hundred Million Dollars ($200,000,000) up
to and including Four Hundred Fifty Million Dollars ($450,000,000)
	  	 	8.0	% 
	 Portion of Annual Net Sales of Products greater than Four Hundred Fifty Million Dollars
($450,000,000)
	  	 	10.0	% 

 (b) Royalty Term. Licensee’s obligations to pay royalties under Section 5.1 (“Royalty
Term”) shall commence on the First Commercial Sale of a Product in the Territory and shall continue until the later to occur of: (a) expiration of all Angionetics Patents covering the manufacture, use or sale of the Compound and/or
Product, in each case, in the Territory; (b) expiration of Regulatory Exclusivity (as defined below) in the Territory; and (c) fifteen (15) years after the First Commercial Sale of a Product in the Territory (the “Royalty
Term”); provided, however, that after the Royalty Term the royalties paid to Angionetics will not be less than the royalty specified in Section IV.3 of the Technology Transfer Agreement between Schering Aktiengesellschaft, Berlex Inc.,
Collateral Therapeutics, Inc. and Cardium Therapeutics, Inc. (or each of their respective successors) dated October 13, 2005. “Regulatory Exclusivity” shall mean any exclusive marketing rights or data exclusivity rights
conferred by an applicable Regulatory Authority or other governmental authority in the Territory, including any regulatory data protection exclusivity and any extensions to such exclusivity rights. 

(c) Royalty Reduction. Upon Regulatory Approval and commercial sale within the Territory of a competitive angiogenic gene therapy
product in the Field by a Third Party, the royalties payable by Licensee to Angionetics under Section 5.1(a) from Net Sales the Territory will be reduced to fifty percent (50%) of the rate set forth in Section 5.1(a). 

(d) Reports and Royalty Payment. Within forty-five (45) days after the end of each calendar quarter, Licensee shall deliver to
Angionetics a report setting out in reasonable detail the information necessary to calculate the royalty payments due under this Section 5.1 with respect to Net Sales made in that calendar quarter, including: 

(i) units of the Product(s) sold in the Territory during the relevant calendar quarter; 

  
 - 10 - 

 (ii) gross sales of the relevant Products in the Territory in the relevant calendar quarter;

 (iii) Net Sales in the relevant calendar quarter on a Product-by-Product basis; and 

(iv) all relevant deductions or credits due to Licensee in accordance with the terms of this Agreement. 

Any amounts due under Section (a) for such calendar quarter shall accompany such statement. 

5.2 Sublicense Payments. In addition to the royalty payments in Section 5.1, if Licensee grants a Sublicense to a Third Party then
Licensee shall pay to Angionetics: 
 (a) Twenty-five percent (25%) of any Net Proceeds received within forty-eight (48) months
after the Effective Date; and 
 (b) ten percent (10%) of any Net Proceeds received more than forty-eight (48) months after the
Effective Date. 
 ARTICLE 6 

PAYMENTS; BOOKS AND RECORDS 
 6.1
Payment Method. All payments under this Agreement shall be made by bank wire transfer in immediately available funds to an account designated by the Party to which such payments are due. Any payments or portions thereof due under this
Agreement that are not paid by the date such payments are due under this Agreement shall bear interest at a rate equal to: (i) the prime rate as reported by Citibank N.A., plus one percent (1%) per year; or (ii) if lower, the maximum
rate permitted by law; calculated on the number of days such payment is delinquent, compounded annually and computed on the basis of a three hundred sixty five (365) day year and the actual days elapsed. The applicable interest rate shall be
adjusted each time there shall be a change in the prime rate announced by Citibank N.A. This Section 6.1 shall in no way limit any other remedies available to the Parties. 

Withholding Taxes. If laws or regulations require withholding by Licensee of any taxes imposed upon Angionetics on account of any royalties or other
payments paid under this Agreement, such taxes shall be deducted by Licensee as required by law from such payment and shall be paid by Licensee to the proper taxing authorities. Official receipts of payment of any withholding tax shall be secured
and sent to Angionetics as evidence of such payment. The Parties will exercise their reasonable efforts to ensure that any withholding taxes imposed are reduced as far as possible under the provisions of any applicable tax treaty, and shall
cooperate in filing any forms required for such reduction. 
 6.2 U.S. Dollars. All dollar amounts specified in, and all payments
made under this Agreement, shall be in U.S. dollars. 

  
 - 11 - 

 6.3 Records; Inspection. Licensee shall keep, and require its Affiliates to keep,
complete, true and accurate books of accounts and records for the purpose of determining the amounts payable to Angionetics pursuant to this Agreement. Such books and records shall be kept for at least three (3) years following the end of the
calendar quarter to which they pertain. Such records will be open for inspection during the three (3) year period after Licensee’s payment of the amount to which such records relate or the due date of such payment, whichever is later, by
an independent auditor chosen by Angionetics and reasonably acceptable to Licensee for the purpose of verifying the amounts payable by Licensee hereunder. Such inspections may be made no more than once each calendar year, at reasonable times and on
thirty (30) days’ prior written notice. Such records for any particular calendar quarter shall be subject to no more than one inspection. The independent auditor shall be obligated to execute a reasonable confidentiality agreement prior to
commencing any such inspection. Inspections conducted under this Section 6.4 shall be at the expense of Angionetics, unless a variation or error producing an underpayment in amounts payable exceeding five percent (5%) of the amount paid
for a period covered by the inspection is established, in which case all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered shall be paid by Licensee, together with interest on such unpaid amounts
at the rate set forth in Section 6.1 above. The Parties will endeavor in such inspection to minimize disruption of Licensee’s normal business activities to the extent reasonably practicable. 

ARTICLE 7 

MANUFACTURING, DELIVERY AND SUPPLY 

7.1 Manufacturing by Angionetics. During the term of the Agreement, Angionetics shall be responsible to facilitate and coordinate the
U.S.-based contract manufacturing of Products and will deliver, at Licensee’s sole discretion, either Compound as frozen bulk supply Ad5FGF-4 or vialed finished goods of the Generx Product, to Licensee through its manufacturing agreement with
SAFC®, located in Carlsbad, California or other licensed manufacturer. If Licensee elects to receive frozen bulk supply Ad5FGF-4, then Licensee shall be responsible to hydrate, vial and
package Product finished goods for the Territory. The transfer price that Licensee shall pay to Angionetcs for fully-vialed finished goods shall be one hundred twenty percent (120%) of Angionetics’ out-of-pocket, manufacturing costs, with
fifty percent (50%) payable prior to shipment with the remaining balance due within thirty (30) working days from Licensee’s receipt of the finished goods. In the event that Licensee establishes a manufacturing capability to utilize
frozen bulk supply of Ad5FGF-4 to hydrate, vial and package finished Product, in accordance with the rules and regulations of the CFDA, Angionetics will agree to adjust the transfer price for Compound accordingly. Licensee shall bear all risk and
costs associated to the shipment of finished goods from the U.S.-based manufacturing facility to the Licensee. Prior to the shipment of any Compound or Product for clinical trials, the Parties shall enter into a separate supply agreement (the
“Supply Agreement”) which will include provisions related to forecasting, order, shipping and delivery, and payment terms, quality control, audit rights, and regulatory responsibilities. 

7.2 Back-up Supply. 
 (a)
Licensee shall be entitled to manufacture either Compound or Products for the Territory, if: (i) Angionetics is unable to supply all of Licensee’s demand for either 

  
 - 12 - 

 
Ad5FGF-4 or finished Generx Product as agreed; (ii) Angionetics’ third party manufacturer has a regulatory issue; (iii) at Licensee’s reasonable request, provided that
Licensee has sold at least 50,000 units of Product, within the ExclusiveTerritory, for at least two out of three previous calendar years, or (iv) at Licensee’s request if the selling price of Generx in the Exclusive Territory materially
decreases as a result of (x) competition in the Exclusive Territory or (y) pricing adjustment to maintain Licensee’s market share. 

(b) Angionetics agrees, upon Licensee’s request, to transfer to Licensee all Angionetics Know-How related to manufacturing the Compound
and Product to Licensee, and to use Commercially Reasonable Efforts to cause its third party contract manufacturer(s), including SAFC®, located in Carlsbad, California, to do the same. 

ARTICLE 8 
 CONFIDENTIALITY

 8.1 Confidential Information. Except as expressly provided in this Agreement, the Parties agree that the receiving Party shall not
publish or otherwise disclose and shall not use for any purpose any information furnished to it by the other Party hereto pursuant to this Agreement (collectively, “Confidential Information”). Notwithstanding the foregoing,
Confidential Information shall not include information that, in each case as demonstrated by written documentation: 
 (a) was already known
to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure or, as shown by written documentation, was developed by the receiving Party prior to its disclosure by the disclosing Party; 

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 

(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement; 
 (d) was subsequently lawfully disclosed to the receiving Party by a person
other than the disclosing Party, and who did not directly or indirectly receive such information from disclosing Party; or 
 (e) is
developed by the receiving Party without use of or reference to any Confidential Information disclosed by the disclosing Party. 
 8.2
Permitted Disclosures. Notwithstanding the provisions of Section 8.1 above and subject to Sections 8.3 and 8.4 below, each Party hereto may use and disclose the other Party’s Confidential Information to its Affiliates,
licensees, contractors and any other Third Parties to the extent such use and/or disclosure is reasonably necessary to exercise the rights granted to it, or reserved by it, under this Agreement (including in the case of Angionetics, in connection
with the development, manufacture and/or commercialization of the Compound and/or Products for outside the Territory), prosecuting or defending litigation, complying with Applicable Laws, 

  
 - 13 - 

 
submitting information to tax or other governmental authorities or conducting clinical trials hereunder with respect to any Product. If a Party is required by law or regulations to make any such
disclosure of the other Party’s Confidential Information, to the extent it may legally do so, it will give reasonable advance notice to such other Party of such disclosure and, save to the extent inappropriate in the case of patent applications
or otherwise, will use its good faith efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise). For any other disclosures of the other Party’s
Confidential Information, including to Affiliates, licensees, contractors and/or other Third Parties, a Party shall ensure that the recipient thereof is bound by a written confidentiality agreement as materially protective of such Confidential
Information as this Article 8. 
 8.3 Confidential Terms. Each Party agrees not to disclose to any Third Party the terms of this
Agreement without the prior written consent of the other Party hereto, except for permitted disclosures under Section 8.2 and that each Party may disclose the terms of this Agreement: to advisors (including financial advisors, attorneys and
accountants), actual or potential acquisition partners or private investors, and others on a need to know basis, in each case under an appropriate confidentiality arrangement substantially equivalent to the terms of this Article 8.
Notwithstanding the foregoing, the Parties shall agree upon a mutual press release to announce the execution of this Agreement, a draft of which is attached as Exhibit 8.3. Thereafter, each Party may each disclose to Third Parties the
information contained in such press release without the need for further approval by the other Party. 
 8.4 Publication of Product
Information. Prior to the First Commercial Sale, Licensee may publish, publicly present and/or submit for written or oral publication a manuscript, abstract or the like that includes Data or other information relating to the Compound and/or
Products that has not previously published pursuant to this Section 8.4 only upon the mutual agreement of the Parties. The contribution of each Party shall be noted in all publications or presentations by acknowledgment or co-authorship,
whichever is appropriate. After First Commercial Sale, Licensee may publish, publicly present and/or submit for written or oral publication a manuscript, abstract or the like that includes Data or other information generated by Licensee or its
Affiliates or sublicensees relating to the Compound and/or Products that has not previously published pursuant to this Section 8.4 only upon the mutual agreement of the Parties. 

8.5 Prior Non-Disclosure Agreements. Upon execution of this Agreement, the terms of this Article 8 shall supersede any prior
non-disclosure, secrecy or confidentiality agreement between the Parties with respect to information relating to the Compound, Products and/or the business or operations of a Party. Any such information disclosed under such prior agreements shall be
deemed disclosed under this Agreement. 
 ARTICLE 9 

PATENT PROSECUTION AND ENFORCEMENT 

9.1 Ownership of Inventions. As between the Parties, title to all inventions and other intellectual property made (a) solely by
personnel of Licensee or any of its Affiliates in connection with this Agreement shall be owned by Licensee; (b) solely by personnel of Angionetics or any of its Controlled Affiliates in connection with this Agreement shall be owned by
Angionetics; and (c) jointly by personnel of Angionetics and Licensee (or their respective 

  
 - 14 - 

 
Affiliates) in connection with this Agreement shall be jointly owned by Angionetics and Licensee. Prosecution of any Patent with respect to such jointly-owned inventions and intellectual property
shall be solely as mutually agreed. Except as expressly provided in this Agreement, it is understood that neither Party shall have any obligation to obtain any approval of, nor pay a share of the proceeds to, the other Party to practice, enforce,
license, assign or otherwise exploit such jointly-owned inventions or intellectual property, and each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval or accounting. 

9.2 Prosecution and Maintenance of Angionetics Patents. 

(a) Angionetics Patent Rights. Angionetics shall have the right, at its expense, to control the Prosecution and Maintenance of Patents
included in the Angionetics Patents as of the Effective Date, or which may be filed in any country after the Effective Date. Angionetics shall consult with Licensee in good faith regarding the Prosecution and Maintenance of such Angionetics Patents
in the Territory and shall take into account Licensee’s reasonable comments related to such matters to the extent such comments pertain to the Compound or Product, or a method of use or manufacture of any of the foregoing. If Angionetics
determines not to file any Patent, or to abandon any Patent within the Angionetics Patents in the Territory, with respect to any Product, and/or manufacturing and/or use thereof in the Field, as applicable, Angionetics shall provide Licensee with at
least sixty (60) days’ written notice of such decision, prior to the deadline for filing any such Patent or the date on which such abandonment would become effective. In such event, Licensee shall have the right, at its option, to control
the Prosecution and Maintenance of such Patent. For the purposes of this Section 9.2, “Prosecution and Maintenance” (including variations such as “Prosecute and Maintain”) shall mean, with respect to a Patent, the
preparing, filing, prosecuting and maintenance of such Patent, as well as re-examinations, reissues and requests for Patent term extensions and the like with respect to such Patent, together with the conduct of interferences, the defense of
oppositions and other similar proceedings with respect to a Patent. 
 (b) Cooperation. Each Party shall cooperate with the other
Party in connection with all activities relating to the Prosecution and Maintenance of the Angionetics Patents undertaken by such other Party pursuant to this Section 9.2, including: (i) making available in a timely manner any documents or
information such other Party reasonably requests to facilitate such other Party’s Prosecution and Maintenance of the Angionetics Patents pursuant to this Section 9.2; and (ii) if and as appropriate, signing (or causing to have signed)
all documents relating to the prosecution and maintenance of any Angionetics Patents by such other Party. Each Party shall also promptly provide to the other Party all information reasonably requested by such other Party with regard to such
Party’s activities pursuant to this Section 9.2. Licensee shall hold all information disclosed to it under this Section as Confidential Information. 

9.3 Enforcement. 
 (a)
Notice. Subject to the provisions of this Section 9.3, in the event that Licensee reasonably believes that any Angionetics Patents in the Territory are infringed by a third party, or any of the Angionetics Patents are subject to a
declaratory judgment action in the Territory arising from such infringement, in each case with respect to the manufacture, sale or use of a product containing a Compound (an “Infringing Product”), Licensee shall promptly notify

  
 - 15 - 

 
Angionetics. Licensee shall have the initial right (but not the obligation), at its own expense, to enforce the Angionetics Patents with respect to such infringement or defend any declaratory
judgment action with respect thereto in the Territory (for purposes of this Section 9.3, an “Enforcement Action”). Angionetics shall, at its expense, have the right to join in as a party plaintiff and, in any event, shall give
reasonable assistance to such Enforcement Action. Licensee shall keep Angionetics reasonably informed of the progress of any such Enforcement Action. Licensee agrees not to settle any Enforcement Action, or make any admissions or assert any position
in such Enforcement Action, in a manner that would adversely affect validity, enforceability or scope of the Angionetics Patents, without the prior written consent of Angionetics, which shall not be unreasonably withheld or delayed. 

(b) Initiating Enforcement Actions. In the event that Licensee fails to initiate an Enforcement Action to enforce the Angionetics
Patents against a commercially significant infringement by a Third Party in the Territory, which infringement consists of the manufacture, sale or use of an Infringing Product in the Field in the Territory, within one hundred eighty (180) days
after a request by Angionetics to initiate such Enforcement Action, Angionetics may initiate an Enforcement Action against such infringement at its own expense. Upon the request of Angionetics, Licensee shall cooperate in such Enforcement Action at
Angionetics’ expense. Angionetics shall keep Licensee reasonably informed of the progress of any such Enforcement Action. Licensee shall, at its expense, have the right to join in as a party plaintiff and to give reasonable assistance to such
Enforcement Action. Angionetics agrees not to settle any Enforcement Action, or make any admissions or assert any position in such Enforcement Action, in a manner that would materially adversely affect the validity, enforceability or scope of any
Angionetics Patents, without the prior written consent of Licensee. 
 (c) Recovery. Licensee and Angionetics shall recover their
respective actual out-of-pocket expenses, or proportionate percentages thereof, associated with any litigation against infringers undertaken pursuant to Section 9.3 above or settlement thereof from any resulting recovery made by either Party.
Any excess amount of such a recovery shall be shared equally between Licensee and Angionetics, to the extent such recovery represents damages arising from an Infringing Product in the Territory. 

(d) Cooperation. The Parties shall keep one another informed of the status of their respective activities regarding any litigation or
settlement thereof concerning any Enforcement Actions described in this Section 9.3 controlled by such Party and shall assist one another and cooperate in any such litigation at the other’s reasonable request (including joining as a party
plaintiff to the extent necessary and requested by the other Party). 
 9.4 Third Party Infringement Claims. If the production, sale
or use of the Compound or a Product for the Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent infringement against Angionetics or Licensee (or their respective Affiliates or licensees) (collectively,
“Infringement Actions”), such Party shall promptly notify the other Party hereto in writing. The Party subject to such Infringement Action shall have the right to direct and control the defense thereof; provided, however, that the
other Party may participate in the defense and/or settlement thereof at its own expense with counsel of its choice. In any event, the Party that is subject to the Infringement Action agrees to keep the other Party hereto reasonably informed of all
material developments in connection with any such Infringement Action. The Party who is subject to the Infringement Action agrees not to settle such 

  
 - 16 - 

 
Infringement Action, or make any admissions or assert any position in such Infringement Action, in a manner that would adversely affect the other Party’s rights with respect to the Compound
or a Product in such other Party’s territory (i.e., in the case of Licensee, the Territory, and in the case of Angionetics, countries outside of the Territory) or the manufacture, use or sale of the Compound or any Product in such other
Party’s respective territory, without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed. 

ARTICLE 10 
 TERM AND
TERMINATION 
 10.1 Term. This Agreement shall commence on the Effective Date, and unless terminated earlier as provided in this
Article 10, shall continue in full force and effect until Licensee has no remaining payment obligations to Angionetics. Upon expiration (but not an earlier termination) of this Agreement, Licensee shall have a perpetual, non-exclusive, fully
paid-up, royalty free license under the Angionetics IP to make, have made, use, sell, offer for sale and import such Product in the Territory. 

10.2 Breach. Either Party to this Agreement may terminate this Agreement in the event the other Party shall have materially breached or
defaulted in the performance of any of its obligations hereunder, and such default shall have continued for ninety (90) days after written notice thereof was provided to the breaching Party by the non-breaching Party. Any such termination shall
become effective at the end of such ninety (90) day period unless the breaching Party has cured any such breach or default prior to the expiration of the ninety (90) day period. 

10.3 Termination For Convenience. Licensee may terminate this Agreement in its entirety for any reason: (a) upon sixty
(60) days’ prior written notice to Angionetics prior to the First Commercial Sale; and (b) upon one hundred twenty (120) days’ prior written notice to Angionetics following the First Commercial Sale. 

10.4 Termination under Securities Purchase Agreement. Angionetics may terminate this Agreement in its entirety in the event that
Pineworld Capital Limited, a Hong Kong limited liability company fails to complete its financing obligations under the terms of that certain Share Purchase Agreement dated June 7, 2016 between Angionetics and Pineworld Capital Limited (the
“Share Purchase Agreement”) as follows: (a) Angionetics may terminate the Agreement at any time following 15 Business Days after the date of the Share Purchase Agreement if Pineworld Capital Limited has failed to complete the
initial closing of the purchase of 200,000 shares of Angionetics Series A Preferred Stock by such date, and (b) Angionetics may terminate the Agreement at any time following September 30, 2016 (such date, or such later date as Angionetics
and Pineworld Capital Limited may agree pursuant to the terms of the Share Purchase Agreement, the “Second Closing Date”) if Huapont has failed to complete the second closing for the purchases of an additional 400,000 shares of
Angionetics Series A Preferred Stock by the Second Closing Date. 

  
 - 17 - 

 ARTICLE 11 

EFFECT OF TERMINATION 
 11.1
Accrued Obligations. The expiration or termination of this Agreement for any reason shall not release either Party from any liability that, at the time of such expiration or termination, has already accrued to the other Party or that is
attributable to a period prior to such expiration or termination, nor will any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach
of this Agreement. 
 11.2 Rights on Termination. This Section 11.2 shall apply upon any termination of Licensee’s rights
under this Agreement in its entirety, excluding only termination of this Agreement pursuant to Section 10.2 for Angionetics’ breach. 

(a) Wind-down Period. 

(i) Development. In the event there are any on-going clinical trials of Product in the Territory and/or any on-going formulation
studies (e.g. stability studies) of Product in the Territory, to the extent so requested by Angionetics, Licensee agrees to either promptly transition such clinical trials and/or formulation studies to Angionetics (or its designee), or continue to
conduct such clinical trials and/or formulation studies, at Angionetics’ expense, and otherwise in accordance with the terms and conditions of this Agreement in effect prior to its termination. 

(ii) Commercialization. If this Agreement expires or is terminated after the First Commercial Sale of Product in the Territory, then
within thirty (30) days of expiration or termination of this Agreement, Licensee shall notify Angionetics of any quantity of the Compound and/or Product remaining in Licensee’s inventory and, if so requested by Angionetics, Licensee shall
transfer to Angionetics (or its designee) all right, title and interest in and to any such quantities of the Compound and/or Product at a price equal to Licensee’s actual cost plus twenty percent (20%). Unless and until Angionetics elects to
purchase any of the inventory, Licensee and its Affiliates may continue to distribute all Products for which Marketing Approval has been obtained in the Territory in accordance with the terms and conditions of this Agreement, for a period not to
exceed twelve (12) months after the effective date of such expiration or termination (for purposes of Section 11.2, the “Wind-down Period”). Notwithstanding any other provision of this Agreement, during the Wind-down Period,
Licensee’s and its Affiliates’ rights with respect to the Compound and Product in the Territory shall be non-exclusive, and Angionetics shall have the right to engage one or more other distributor(s) and/or licensee(s) of the Compound
and/or Products in all or part of the Territory. Any Product sold or disposed by Licensee and its Affiliates in the Territory during the Wind-down Period shall be subject to the applicable payment obligations under Article 5 above. 

(b) Assignment of Regulatory Filings and Marketing Approvals. At Angionetics’ option, which shall be exercised by written notice
to Licensee, Licensee shall, at its expense, assign or cause to be assigned to Angionetics or its designee (or to the extent not so assignable, Licensee shall take all reasonable actions to make available to Angionetics or its designee the benefits
of) all regulatory filings and registrations (including INDs, MAAs and 

  
 - 18 - 

 
Marketing Approvals) for the Compound and/or any Product in the Territory, including any such regulatory filings and registrations made or owned by its Affiliates. In each case, unless otherwise
required by any Applicable Law or requested by Angionetics, the foregoing assignment (or availability) shall be made within ninety (90) days after the effective date of any such expiration or termination of this Agreement. In addition, Licensee
shall, at its expense, promptly provide to Angionetics (in electronic form, to the extent the same exists in electronic form) a copy of all Data pertaining to the Compound and/or Product, to the extent not previously provided to Angionetics and
Angionetics shall have the right to use (and authorize the use of), and to disclose, all such Data following expiration or termination of this Agreement. 

(c) Transition. Licensee shall use Commercially Reasonable Efforts to cooperate with Angionetics and/or its designee to effect a smooth
and orderly transition in the development, sale and on-going marketing, promotion and commercialization of the Compound and Product in the Territory. 

(d) Return of Materials. Within fifteen (15) days after the end of the Wind-down Period (or after the expiration or termination of
this Agreement, in the event there is no Wind-down Period), Licensee shall, at its expense, destroy all tangible items comprising, bearing or containing any Confidential Information of Angionetics, that is in Licensee’s possession or return
such Confidential Information to Angionetics, as Angionetics may direct, at Angionetics’ expense. 
 (e) Royalty to Licensee. If
the termination occurs after completion of a clinical trial in support of Marketing Approval of the Product in the Territory, including after the First Commercial Sale of a Product in the Territory, then Angionetics shall pay to Licensee a royalty
on Net Sales by Angionetics, its Affiliiates or licensees, of the Products in the Territory equal to fifty percent (50%) of the amounts set forth in Section 5.1 in accordance with Article 5, mutatis mutandis. 

11.3 Survival. Upon the expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement
shall terminate except those described in the following Sections: Sections 2.3, 8.1, 8.2, 8.3, 8.5, 11.1, 11.2, 11.3, 13.1, 13.2, 13.3, 13.4, 14.1, 14.2, 14.3, 15.2 ; and, in addition, to the extent that any Product is sold during the Wind-down
Period defined in Section (ii) above, the following Sections shall survive: Sections 5.1 and 5.2. 
 ARTICLE 12 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

12.1 General Representations. Each Party hereby represents and warrants to the other Party as of the Effective Date as follows: 

(a) Duly Organized. Such Party is a corporation duly organized, validly existing and is in good standing under the laws of the
jurisdiction of its incorporation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to
have such would prevent such Party from performing its obligations under this Agreement. 

  
 - 19 - 

 (b) Due Execution; Binding Agreement. This Agreement is a legal and valid obligation
binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary corporate action and do not and will not: (i) require any
consent or approval of its stockholders; (ii) to such Party’s knowledge, violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having
jurisdiction over such Party; nor (iii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which such Party is a party or by which it is bound. 

12.2 Representations and Warranties of Angionetics. Angionetics represents, warrants to Licensee that, as of the Effective Date: 

(a) it has the full right and authority to grant the rights and licenses as provided herein; 

(b) it has not previously granted any right, license or interest in or to the Angionetics Patents, or any portion thereof, that is in conflict
with the rights or licenses granted to Licensee under this Agreement; 
 (c) to its knowledge, there are no actual, pending, alleged or
threatened actions, suits, claims, interference or governmental investigations in the Territory involving the Compound, Product, the Angionetics Patents or the Angionetics Know-How by or against Angionetics, or any of its Affiliates. In particular,
to its best knowledge, there is no pending or threatened product liability action nor intellectual property right litigation in the Territory in relation to the Compound and/or Products; 

(d) all necessary consents, approvals and authorizations of all Regulatory Authorities, other governmental authorities and other persons or
entities required to be obtained by Angionetics in order to enter into this Agreement have been obtained; and 
 (e) there is no actual,
pending, alleged or to the knowledge of Angionetics threatened infringement or misappropriation by a Third Party in the Territory of any of the Angionetics Patents or the Angionetics Know-How; and 

(f) to the knowledge of Angionetics, the manufacture, use, sale or other disposition of Compound and/or Products in or for the Territory does
not and will not infringe or misappropriate any Third Party intellectual property rights. 
 12.3 Representations and Warranties of
Licensee. Licensee represents and warrants to Angionetics that, as of the Effective Date: 
 (a) it has the full right and authority to
grant the rights granted herein; 
 (b) all necessary consents, approvals and authorizations of all Regulatory Authorities, other
governmental authorities and other persons or entities required to be obtained by Licensee in order to enter into this Agreement have been obtained; and 

  
 - 20 - 

 (c) Licensee does not have any knowledge that any of Angionetics’ representations and
warranties set forth in Sections 12.1 and 12.2 above are inaccurate. 
 12.4 DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH
IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR VALIDITY OF
ANY PATENTS ISSUED OR PENDING. 
 ARTICLE 13 

INDEMNIFICATION 
 13.1
Indemnification of Angionetics. Licensee shall indemnify and hold harmless each of Angionetics, its Affiliates and licensees and their respective directors, officers and employees and the successors and assigns of any of the foregoing
(the “Angionetics Indemnitees”), from and against any and all liabilities, damages, penalties, fines, costs, expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Liabilities”) from
any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claim”) incurred by any Angionetics Indemnitee, arising from, or occurring as a result of: (a) the developing, use, marketing, distribution,
import, and/or sale of Compounds and/or Products by or under the authority of Licensee, or (b) any material breach of any representations, warranties or covenants by Licensee in Section 13 above; except to the extent such Third Party
Claims fall within the scope of Angionetics’ indemnification obligations set forth in Section 13.2 below. 
 13.2
Indemnification of Licensee. Angionetics shall indemnify and hold harmless each of Licensee, and its Affiliates and their respective directors, officers and employees and the successors and assigns of any of the foregoing (the
“Licensee Indemnitees”), from and against any and all Liabilities from any Third Party Claims incurred by any Licensee Indemnitee, arising from, or occurring as a result of: (a) the developing, making, having made, use,
marketing, distribution or sale of any Product by Angionetics or its Product licensee(s) outside the Territory, or (b) any material breach of any representations, warranties or covenants by Angionetics in Article 12 above. 

13.3 Procedure. A Party that intends to claim indemnification under Article 13 (the “Indemnitee”) shall promptly
notify the other Party (the “Indemnitor”) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense and/or settlement
thereof. The indemnity arrangement in Article 13 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be
withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim, if prejudicial to its ability to defend such action,
shall relieve such Indemnitor of any liability to the Indemnitee under Article 13, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability that it may have to any Indemnitee otherwise
than under Article 13. The Indemnitee under Article 13 shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification. 

  
 - 21 - 

 13.4 No consequential damages. EXCEPT FOR OBLIGATIONS TO MAKE PAYMENT UNDER THIS AGREEMENT,
LIABILITY FOR BREACH OF CONFIDENTIALITY, OR LIABILITY FOR INFRINGEMENT OR MISAPPROPRIATION OF INTELLECTUAL PROPERTY RIGHTS, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS REPRESENTATIVES BE LIABLE UNDER THIS AGREEMENT TO THE OTHER PARTY OR ANY THIRD
PARTY FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR ENHANCED DAMAGES, LOST PROFITS OR REVENUES OR DIMINUTION IN VALUE, ARISING OUT OF, OR RELATING TO, AND/OR IN CONNECTION WITH ANY BREACH OF THIS AGREEMENT, REGARDLESS OF
(A) WHETHER SUCH DAMAGES WERE FORESEEABLE, (B) WHETHER OR NOT IT WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND (C) THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED 

ARTICLE 14 
 DISPUTE
RESOLUTION 
 14.1 Senior Executives. In the event of any dispute between the Parties arising out of or in connection with this
Agreement, either Party may, by written notice to the other, have such dispute referred to the CEO of Angionetics and the CEO of Licensee for attempted resolution by good faith negotiations within thirty (30) days after such notice is received,
and, in such event, each Party shall cause its representative to meet and be available to attempt to resolve such issue. Notwithstanding the foregoing, neither Party shall be obligated to negotiate for more than thirty (30) days. If the Parties
should resolve such dispute or claim, a memorandum setting forth their agreement will be prepared and signed by both Parties if requested by either Party. 

14.2 Jurisdiction. Any dispute, controversy or claim with respect to the breach, interpretation, performance or enforcement of this
Agreement, not resolved pursuant to Section 14.1 shall be subject to the exclusive jurisdiction of the state and federal courts in the State of Delaware, and each Party hereby submits to such jurisdiction for the resolution of such Dispute and
hereby waives the defense of any inconvenient forum for the maintenance of any action or proceeding in such jurisdiction for such purpose. 

14.3 Interim Relief. Notwithstanding anything in this Article 14 to the contrary, Licensee and Angionetics shall each have the right to
apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other similar interim or conservatory relief, as necessary to protect the right or property of such Party. 

ARTICLE 15 
 GENERAL
PROVISIONS 
 15.1 Force Majeure. If the performance of any part of this Agreement (except for any payment obligation under this
Agreement) by either Party is prevented, restricted, interfered with or delayed by reason of force majeure (including, fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or other labor
disturbance or acts of God), the Party so affected shall, upon giving written notice to the other Party, be excused from such 

  
 - 22 - 

 
performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its reasonable efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 
 15.2 Governing Law. This
Agreement and all questions regarding its validity or interpretation, or the breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without reference to
conflict of law principles. The U.N. Convention on the Sale of Goods shall not apply to this Agreement. 
 15.3 Waiver of Breach.
Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any
time to require performance of any provision of this Agreement shall in no manner affect such Party’s rights at a later time to enforce the same. No waiver by either Party of any condition or term in any one or more instances shall be construed
as a further or continuing waiver of such condition or term or of another condition or term. 
 15.4 Modification. No amendment or
modification of any provision of this Agreement shall be effective unless in writing signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of
dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

15.5 Severability. In the event any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction,
the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect in such
jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. 

15.6 Entire Agreement. This Agreement (including the Exhibits attached hereto) constitutes the entire agreement between the Parties
relating to its subject matter and supersedes all prior or contemporaneous agreements, understandings or representations, either written or oral, between Angionetics and Licensee with respect to such subject matter. 

15.7 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices and other communications between the
Parties relating to, and all written documentation to be prepared and provided under, this Agreement shall be in the English language: (a) delivered personally; (b) sent by registered or certified mail (return receipt requested and postage
prepaid); (c) sent by express courier service providing evidence of receipt, postage pre-paid where applicable; or (d) sent by facsimile (receipt verified and a copy promptly sent by another permissible method of providing notice described
in paragraphs (b), (c) or (d) above), to the following addresses of the Parties or such other address for a Party as may be specified by like notice: 

  
 - 23 - 

			
	 To Angionetics:
  

Angionetics, Inc.
 Telephone: 858-436-1000

Facsimile: 858-436-1001
 Attention: Duane Linstrom
	  	 To Licensee:
  

Pineworld Capital Limited
 FLAT 01A, 10/F CARNIVAL COMMERCIAL

BUILDING 18 JAVA ROAD, NORTH POINT,
 HONG KONG

Attention: Chief Executive Officer

		
	 With a copy to:
  

Sheppard, Mullin, Richter & Hampton LLP
 12275 El Camino
Real, Suite 200,
 San Diego CA 92130
 Telephone:
(858) 720-7469
 Attn: jmercer@sheppardmullin.com
	  	 With a copy to:
  

Wilson, Sonsini, Goodrich & Rosati
 650 Page Mill Road

Palo Alto, CA 94304
 Telephone: (650) 493-3383

Facsimile: (650) 493-6811
 Attention: Karen Wong

 Any notice required or permitted to be given concerning this Agreement shall be effective upon receipt by the
Party to whom it is addressed or within seven (7) days of dispatch whichever is earlier. 
 15.8 Assignment. This Agreement
shall not be assignable by either Party to any Third Party hereto without the written consent of the other Party hereto; except: (i) either Party may assign this Agreement without the other Party’s consent to an entity that acquires
substantially all of the business or assets of the assigning Party, whether by merger, acquisition or otherwise, provided that the Party to whom this Agreement is assigned assumes this Agreement in writing or by operation of law; and
(ii) Licensee may assign this Agreement without the consent of Angionetics to Affiliate. In addition, either Party shall have the right to assign this Agreement to an Affiliate upon written notice to the non-assigning Party; provided that the
assigning Party guarantees the performance of this Agreement by such Affiliate. Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and permitted assigns. A Party assigning this Agreement shall provide
written notice of any assignment to the other Party within five (5) business days after any such permitted assignment. Any assignment of this Agreement in contravention of this Section 15.8 shall be null and void. 

15.9 No Partnership or Joint Venture. Nothing in this Agreement is intended, or shall be deemed, to establish a joint venture or
partnership between Angionetics and Licensee. Neither Party to this Agreement shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to
any contract, agreement or undertaking with any Third Party. 
 15.10 Interpretation. The captions to the several Articles and
Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed to be followed
by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; (c) masculine, feminine and neuter pronouns and 

  
 - 24 - 

 
expressions shall be interchangeable; and (d) the word “will” shall be construed as having the same meaning and effect as the word “shall.” 

15.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of
which together shall constitute one and the same instrument. Signatures to this Agreement delivered by facsimile or other form of electronic transmission (e.g., portable document format (PDF)) will be deemed binding as originals. 

[Signature Page Follows] 

  
 - 25 - 

 EXECUTION VERSION 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above. 

 

					
		 	ANGIONETICS, INC.
			
		 	BY:	 	 /s/ CHRISTOPHER J. REINHARD

		 	NAME: Christopher Reinhard
		 	TITLE: Chief Executive Officer

  

					
		 	PINEWORLD CAPITAL LIMITED
			
		 	BY:	 	 /s/ YIZHOU ZHANG

		 	NAME: Yizhuo Zhang
		 	TITLE: Head of Investment

 Signature Page to Distribution and License Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]